Acute health effects after passive e-vape among patients with COPD – an RCT exposure study

Karin Rosenkilde Laursen, Jakob H. Bønløkke, Merete Bilde, Marianne Glasius, Elisabeth Bendstrup, Søren K. Kjærgaard, Anna-Carin Olin, Torben Sigsgaard

Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskningpeer review


Background: E-cigarette use is dramatically increasing and often permitted in smoke-free areas causing passive vape exposure. Little is known about potential adverse health effects of passive vape and people with respiratory diseases may be more susceptible. Our aim was to investigate local and systemic effects of short-term passive exposure to vape among patients with mild or moderate COPD.Methods: In a randomised double-blinded crossover study non-smoking COPD patients were exposed for four hours at two different exposure conditions separated by 14 days; A) clean filtered air (particles concentration <6 µg/m3) and B) passive vaping (median: 18 µg/m3 (range: 8-333)). E-cigarette users in an adjacent chamber were vaping in situation B and vape-polluted air was passed to the exposure chamber. Health effects including FEV1/FVC, FeNO, Surfactant Protein-A (SP-A) in Particles in Exhaled Air (PExA) and plasma biomarkers were evaluated before, after, and 24 h. after exposures.Results: 16 patients (mean age 68) participated. Exposure to passive vape did not alter FEV1/FVC or FeNO. SP-A in exhaled air was negatively affected by time and exposure to vape, and some plasma biomarkers (citrate, phospholipids and free cholesterol in very large HDL plus triglycerides in medium HDL) increased significantly after exposure to vape alone.Conclusions: At the exposure levels in the study, SP-A in exhaled particles, citrate and some plasma biomarkers in patients with COPD were affected by passive vaping indicating inflammation and atherogene activity. We recommend that passive vape exposure should be further studied.FootnotesCite this article as: European Respiratory Journal 2020; 56: Suppl. 64, 4387.This abstract was presented at the 2020 ERS International Congress, in session “Respiratory viruses in the "pre COVID-19" era”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at (ERS member access only).
TidsskriftEuropean Respiratory Journal
Udgave nummerSuppl. 64
StatusUdgivet - 7 sep. 2020
BegivenhedERS International Congress: Virtual - Virtual
Varighed: 7 sep. 20209 sep. 2020
Konferencens nummer: 30


KonferenceERS International Congress